Mineralys Therapeutics Inc (MLYS) Stock Price, Quote & News

Company Profile

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2...

Industry: Biotechnology

Sector: Healthcare

Phone: 888 378 6240

Website: mineralystx.com

Address:

150 N. Radnor Chester Rd., Suite F200, Radnor, United States

Quantumup Mar. 13 at 3:09 PM

BofA⬆️ Mineralys' PT to $51 from $46 and reiterated at a Buy, separately Stifel on $MLYS said: We reiterate our Buy rating, $52 TP. $AZN $ALNY - $RHHBY $NVS Here's what else Stifel had to say: https://x.com/Quantumup1/status/2032473479035936901?s=20

0 · Reply

StocktwitsEarnings Mar. 12 at 9:21 PM

$MLYS Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.40 up 59.18% YoY • Mineralys Therapeutics Inc anticipates continued significant losses, expecting cash, cash equivalents, and investments of $656.6M as of December 31, 2025, to fund operations for at least twelve months, with a PDUFA target action date of December 22, 2026, for lorundrostat.

0 · Reply

DonCorleone77 Mar. 12 at 6:05 PM

$MLYS Mineralys Therapeutics Inc options imply 6.5% move in share price post-earnings Pre-earnings options volume in Mineralys Therapeutics Inc is normal with calls leading puts 5:1. Implied volatility suggests the market is anticipating a move near 6.5%, or 0c, after results are released. Median move over the past eight quarters is 0.9%.

0 · Reply

ZacksResearch Mar. 11 at 4:26 PM

$MLYS pops after a key FDA milestone — but the real date to watch is Dec. 22, 2026. Shares are rising after the FDA accepted the NDA for lorundrostat to treat hypertension, officially putting the drug on the regulatory review path with a decision expected by Dec. 22, 2026. 📈 See what this regulatory step could mean 👉 https://www.zacks.com/stock/news/2882426/mineralys-stock-rises-as-fda-accepts-nda-for-hypertension-drug?cid=sm-stocktwits-2-2882426-teaser-36994&ADID=SYND_STOCKTWITS_TWEET_2_2882426_TEASER_36994

0 · Reply

ZacksResearch Mar. 11 at 3:26 PM

$MLYS jumps 4.4% on FDA acceptance of lorundrostat NDA 🚀 The potential approval could bring a new treatment for resistant hypertension, backed by successful clinical trials showing safety and blood pressure reduction. However, shares are down 21.6% YTD. Full story and analysis here 👉 https://www.zacks.com/stock/news/2882426/mineralys-stock-rises-as-fda-accepts-nda-for-hypertension-drug?cid=sm-stocktwits-2-2882426-body-36993&ADID=SYND_STOCKTWITS_TWEET_2_2882426_BODY_36993

0 · Reply

SannieVerraderlijk Mar. 10 at 8:38 PM

$MLYS Opened position, buyout candidate

0 · Reply

Arcides Mar. 10 at 4:24 PM

$MLYS this cut the last offering price today and is bouncing..25

0 · Reply

OpenOutcrier Mar. 10 at 12:10 PM

$MLYS (-3.5% pre) Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results https://ooc.bz/l/96082

0 · Reply

notreload_ai Mar. 9 at 9:58 PM

$MLYS receives FDA acceptance of NDA for lorundrostat for hypertension. PDUFA target date: December 22, 2026. Explore-OSA missed primary endpoint but demonstrated meaningful BP reduction. https://notreload.xyz/fda-accepts-mineralys-lorundrostat-nda-for-hypertension/

0 · Reply

aletz Mar. 6 at 9:14 AM

$MLYS https://www.biostockinfo.com/biotech-catalyst-ai-scanner-march-wk122026/ Featured in the AI Catalyst Scanner for the second week of March. This scanner integrates advanced AI research with machine learning patterns, leveraging over a decade of data alongside catalyst-driven quality and technical indicators. Disclaimer: BSI score is a rating derived from combined AI and ML models and does not guarantee specific outcomes.

0 · Reply

Mineralys Therapeutics, Inc. (MLYS) Q4 2025 Earnings Call Transcript

Mar 12, 2026, 4:05 PM EDT - 2 days ago

Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

Mar 9, 2026, 4:30 PM EDT - 5 days ago

Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results

Mar 9, 2026, 8:00 AM EDT - 5 days ago

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026

Feb 26, 2026, 4:05 PM EST - 16 days ago

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Jan 6, 2026, 8:00 AM EST - 2 months ago

Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026

Dec 28, 2025, 8:03 AM EST - 2 months ago

Mineralys: Pre-NDA Feedback Sets Stage For A Pivotal 2026

Dec 12, 2025, 11:00 AM EST - 3 months ago

Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup

Nov 26, 2025, 4:05 PM EST - 3 months ago

Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Nov 10, 2025, 7:11 PM EST - 4 months ago

Mineralys Therapeutics, Inc. (MLYS) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 4:05 PM EST - 4 months ago

Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 7, 2025, 6:10 PM EST - 4 months ago

Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025

Oct 21, 2025, 8:00 AM EDT - 5 months ago

Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025

Oct 1, 2025, 3:17 PM EDT - 5 months ago

Mineralys: Lorundrostat Continues To Deliver Hypertension Market Expansions

Sep 30, 2025, 8:00 AM EDT - 5 months ago

Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension

Sep 19, 2025, 12:53 PM EDT - 6 months ago

3 Potential Biotech Acquisition Targets

AZN ETNB INCY SNDX TVTX

Sep 5, 2025, 9:00 AM EDT - 6 months ago

Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need

Sep 4, 2025, 4:01 PM EDT - 6 months ago

Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 3, 2025, 8:17 AM EDT - 6 months ago

Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

BRKR

Sep 2, 2025, 9:33 PM EDT - 6 months ago

Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock

Sep 2, 2025, 4:01 PM EDT - 6 months ago

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

Aug 13, 2025, 12:16 AM EDT - 7 months ago

Mineralys Therapeutics, Inc. (MLYS) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 7 months ago

Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 4, 2025, 4:05 PM EDT - 7 months ago

Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025

Jun 30, 2025, 11:17 AM EDT - 9 months ago

Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat

Jun 17, 2025, 9:57 AM EDT - 9 months ago

Mineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive Patients With Chronic Kidney Disease, Stock Jumps

Jun 17, 2025, 7:00 AM EDT - 9 months ago

Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria

May 24, 2025, 4:30 AM EDT - 10 months ago

Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)

May 20, 2025, 8:00 AM EDT - 10 months ago

Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection

May 12, 2025, 8:20 PM EDT - 10 months ago

Mineralys Therapeutics, Inc. (MLYS) Q1 2025 Earnings Conference Call Transcript

May 12, 2025, 4:05 PM EDT - 10 months ago

Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 7, 2025, 8:00 AM EDT - 11 months ago

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

May 5, 2025, 4:05 PM EDT - 11 months ago

Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025

Apr 23, 2025, 5:23 PM EDT - 11 months ago

Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)

Mar 29, 2025, 2:30 PM EDT - 1 year ago

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

Mar 18, 2025, 4:01 PM EDT - 1 year ago

Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo

Mar 12, 2025, 8:36 AM EDT - 1 year ago

Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

LDI MOMO

Mar 11, 2025, 10:20 PM EDT - 1 year ago

Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock

Mar 10, 2025, 6:25 PM EDT - 1 year ago

Mineralys: Prospects Just Got Better With Successful Pivotal Data Readouts

Mar 10, 2025, 1:50 PM EDT - 1 year ago

Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate

Mar 10, 2025, 1:09 PM EDT - 1 year ago

Dow Tumbles Over 600 Points; Mineralys Therapeutics Shares Spike Higher

Mar 10, 2025, 7:12 AM EDT - 1 year ago

Mineralys Therapeutics' blood pressure drug meets goal in trials

Mar 10, 2025, 7:00 AM EDT - 1 year ago

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

Mar 7, 2025, 4:01 PM EST - 1 year ago

Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET

Feb 12, 2025, 1:38 PM EST - 1 year ago

Mineralys Therapeutics, Inc. (MLYS) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 7:00 AM EST - 1 year ago

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Feb 5, 2025, 4:05 PM EST - 1 year ago

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025

Jan 19, 2025, 8:18 PM EST - 1 year ago

Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension

Quantumup Mar. 13 at 3:09 PM

0 · Reply

StocktwitsEarnings Mar. 12 at 9:21 PM

0 · Reply

DonCorleone77 Mar. 12 at 6:05 PM

0 · Reply

ZacksResearch Mar. 11 at 4:26 PM

0 · Reply

ZacksResearch Mar. 11 at 3:26 PM

0 · Reply

SannieVerraderlijk Mar. 10 at 8:38 PM

$MLYS Opened position, buyout candidate

0 · Reply

Arcides Mar. 10 at 4:24 PM

$MLYS this cut the last offering price today and is bouncing..25

0 · Reply

OpenOutcrier Mar. 10 at 12:10 PM

$MLYS (-3.5% pre) Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results https://ooc.bz/l/96082

0 · Reply

notreload_ai Mar. 9 at 9:58 PM

0 · Reply

aletz Mar. 6 at 9:14 AM

0 · Reply

BillionerOfKing Mar. 3 at 1:04 AM

$MLYS Current Stock Price: $29.35 Contracts to trade: $30.0 MLYS Mar 20 2026 Call Entry: $2.90 Exit: $4.75 ROI: 64% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

BuffettsDad Feb. 28 at 1:20 AM

$MLYS $45C for April bought at $1 $QQQ $SPY

0 · Reply

TeresaTrades Feb. 27 at 2:39 PM

Largest PUT OI decreases $MLYS $HUN $NVO $MARA $EOSE

0 · Reply

TeresaTrades Feb. 27 at 2:36 PM

Largest CALL OI decreases $MLYS $EOSE $B $DOW $CSX

0 · Reply

CyclePhase Feb. 18 at 3:46 PM

$MLYS Minerales y Logística is a speculative materials exposure. Asset monetization is required for rerating. Volatility remains elevated.

0 · Reply

Jakeipedia Feb. 18 at 3:34 PM

$MLYS added!

0 · Reply

Jakeipedia Feb. 11 at 10:38 PM

$MLYS can we get top line OSA trial data tomorrow 🙏

0 · Reply

ChessGM Feb. 9 at 5:29 PM

$MLYS Very strong lately. BO in the cards? https://youtu.be/UGquZKb1y4w

0 · Reply

G101SPM Feb. 6 at 7:17 PM

#OPTIONACTION $MLYS Mar 25 puts (volume: 46.1K, open int: 23.1K, implied vol: ~110%, prev day implied vol: 70%). 22.9K traded in a single transaction. Co is expected to report earnings late February. $HIMS Weekly Feb06 20 puts (volume: 19.8K, open int: 13.9K, implied vol: ~108%, prev day implied vol: 70%). 1K traded in a single transaction. FDA Director Dr. Marty Makary says "FDA will take swift action against companies mass-marketing illegal copycat drugs, claiming they are similar to FDA-approved products. The FDA cannot verify the quality, safety, or effectiveness of non-approved drugs." Co is confirmed to report earnings February 23 after the close.

0 · Reply

VolumeAlchemy Feb. 4 at 9:47 AM

$MLYS automotive software, connected vehicle trend

0 · Reply

Theflash88 Feb. 4 at 1:33 AM

$MLYS Green on a very red day..I’ll take it..

0 · Reply

garygb Jan. 11 at 9:47 PM

$MLYS High hopes here.

0 · Reply

Market Cap	2.07B
Revenue (ttm)	0.00
Net Income (ttm)	-177.81M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,393,500
Avg Vol	1,196,968
Day's Range	N/A - N/A
Shares Out	79.14M
Stochastic %K	27%
Beta	0.57
Analysts	Strong Sell
Price Target	$50.88